# Champions Oncology, Inc.: overview CSBR · Nasdaq · CIK 771856 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Apr 30 Pages: [Overview](/companies/csbr.md) · [Financials](/companies/csbr/financials.md) · [Filings](/companies/csbr/filings.md) · [Insiders](/companies/csbr/insiders.md) Latest reported revenue: [$15.2m](/filings/0001628280-26-061519.md) for Q1 FY2027, three months to 2026-07-31, from the 10-Q filed Sep 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-061519). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [13.5](/filings/0001628280-25-057082.md) | [17.0](/filings/0001628280-26-017345.md) | [12.4 d](/filings/0001628280-26-049834.md) | [14.0](/filings/0001628280-26-061519.md) | [15.0](/filings/0001628280-25-057082.md) | [16.6](/filings/0001628280-26-017345.md) | [13.8 d](/filings/0001628280-26-049834.md) | [15.2](/filings/0001628280-26-061519.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [5.4%](/filings/0001628280-25-057082.md) | [26.4%](/filings/0001628280-26-017345.md) | [(16.2%) d](/filings/0001628280-26-049834.md) | [(3.8%)](/filings/0001628280-26-061519.md) | [1.2%](/filings/0001628280-25-057082.md) | [(1.7%)](/filings/0001628280-26-017345.md) | [(3.8%) d](/filings/0001628280-26-049834.md) | [(2.7%)](/filings/0001628280-26-061519.md) | | Net margin | % | [5.4%](/filings/0001628280-25-057082.md) | [26.4%](/filings/0001628280-26-017345.md) | [(14.9%) d](/filings/0001628280-26-049834.md) | [(3.3%)](/filings/0001628280-26-061519.md) | [1.8%](/filings/0001628280-25-057082.md) | [(1.7%)](/filings/0001628280-26-017345.md) | [(4.8%) d](/filings/0001628280-26-049834.md) | [(2.8%)](/filings/0001628280-26-061519.md) | | Diluted EPS | $ per share | [0.05](/filings/0001628280-25-057082.md) | [0.31](/filings/0001628280-26-017345.md) | not reported | [(0.03)](/filings/0000771856-25-000023.md) | [0.02](/filings/0001628280-25-057082.md) | [(0.02)](/filings/0001628280-26-017345.md) | not reported | not reported | | Free cash flow | $m | [(0.4) d](/filings/0001628280-25-057082.md) | [0.4 d](/filings/0001628280-26-017345.md) | [6.6 d](/filings/0001628280-26-049834.md) | [0.6](/filings/0001628280-26-061519.md) | [(2.0) d](/filings/0001628280-25-057082.md) | [(1.4) d](/filings/0001628280-26-017345.md) | [(2.2) d](/filings/0001628280-26-049834.md) | [(0.5)](/filings/0001628280-26-061519.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-04-30) | FY2023 (2023-04-30) | FY2024 (2024-04-30) | FY2025 (2025-04-30) | FY2026 (2026-04-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [49.1](/filings/0001628280-23-025464.md) | [53.9](/filings/0001628280-24-032321.md) | [50.2](/filings/0001628280-25-035765.md) | [56.9](/filings/0001628280-26-049834.md) | [59.4](/filings/0001628280-26-049834.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [1.2%](/filings/0001628280-23-025464.md) | [(9.8%)](/filings/0001628280-24-032321.md) | [(14.7%)](/filings/0001628280-25-035765.md) | [8.0%](/filings/0001628280-26-049834.md) | [(1.9%)](/filings/0001628280-26-049834.md) | | Net margin | % | [1.1%](/filings/0001628280-23-025464.md) | [(9.9%)](/filings/0001628280-24-032321.md) | [(14.5%)](/filings/0001628280-25-035765.md) | [8.3%](/filings/0001628280-26-049834.md) | [(2.0%)](/filings/0001628280-26-049834.md) | | Diluted EPS | $ per share | [0.04](/filings/0001628280-23-025464.md) | [(0.39)](/filings/0001628280-24-032321.md) | [(0.54)](/filings/0001628280-25-035765.md) | [0.33](/filings/0001628280-26-049834.md) | [(0.08)](/filings/0001628280-26-049834.md) | | Free cash flow | $m | [4.1](/filings/0001628280-23-025464.md) | [1.1](/filings/0001628280-24-032321.md) | [(7.0)](/filings/0001628280-25-035765.md) | [7.0](/filings/0001628280-26-049834.md) | [(5.0)](/filings/0001628280-26-049834.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/csbr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BATTERY MANAGEMENT CORP.](/funds/1548594.md) | 2026-06-30 | $14.9m | 2,421,673 | | Unchanged | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $10.6m | 1,713,720 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.9m | 301,353 | | Added +1,833 | | [TOCQUEVILLE ASSET MANAGEMENT L.P.](/funds/883961.md) | 2026-06-30 | $1.8m | 295,658 | | Reduced −24,016 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.5m | 235,400 | | Reduced −6,900 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $1.3m | 214,058 | | Added +192,225 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $856.5k | 139,039 | | Reduced −6,500 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $799.9k | 129,848 | | Added +5,948 | | [Mink Brook Asset Management LLC](/funds/2052205.md) | 2026-06-30 | $685.8k | 111,338 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $470.1k | 76,300 | | Reduced −877 | ## Recent filings [All 542 filings](/companies/csbr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 16:15 ET | [8-K](/filings/0001628280-26-066087.md) | 5.07 Shareholder vote results | 0001628280-26-066087 | | 2026-09-11 | 18:51 ET | [10-Q](/filings/0001628280-26-061519.md) | Quarterly report, period 2026-07-31 | 0001628280-26-061519 | | 2026-09-10 | 20:46 ET | [8-K](/filings/0001628280-26-061383.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-061383 | | 2026-08-28 | 19:35 ET | [DEF 14A](/filings/0001628280-26-059373.md) | Proxy statement, period 2026-08-27 | 0001628280-26-059373 | | 2026-07-27 | 20:45 ET | [10-K](/filings/0001628280-26-049834.md) | Annual report, period 2026-04-30 | 0001628280-26-049834 | | 2026-07-27 | 20:31 ET | [8-K](/filings/0001628280-26-049822.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-049822 | | 2026-03-30 | 17:16 ET | [8-K](/filings/0001628280-26-021941.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-021941 | | 2026-03-12 | 20:56 ET | [10-Q](/filings/0001628280-26-017345.md) | Quarterly report, period 2026-01-31 | 0001628280-26-017345 | | 2026-03-12 | 20:17 ET | [8-K](/filings/0001628280-26-017259.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-017259 | | 2025-12-15 | 21:59 ET | [10-Q](/filings/0001628280-25-057082.md) | Quarterly report, period 2025-10-31 | 0001628280-25-057082 | ## Latest annual report [Form 10-K for the fiscal year ended Apr 30, 2026](/filings/0001628280-26-049834.md), filed Jul 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 771856 - Tickers: CSBR - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.